Protein carriers of conjugate vaccines Characteristics, development, and clinical trials

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 12, 2013, Pages 2505-2523

  Pichichero, Michael E ^a  

^a ROCHESTER GENERAL HOSPITAL   (United States)

Author keywords

Carrier proteins; Conjugate vaccines; CRM197; Diphtheria toxoid; Haemophilus influenzae protein D; Meningococcal outer membrane protein complex; Streptococcus pneumoniae; Tetanus toxoid

Indexed keywords

BACTERIAL PROTEIN; CARRIER PROTEIN; DIPHTHERIA TOXIN; DIPHTHERIA TOXOID; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MENINGITIS VACCINE; OUTER MEMBRANE PROTEIN; PLACEBO; POLYRIBOSYL RIBITOL PHOSPHATE; POLYSACCHARIDE; STREPTOCOCCUS VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANTIGEN BINDING; BACTERIAL COLONIZATION; BINDING AFFINITY; DRUG CONJUGATION; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE TYPE B; HERD IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; MENINGOCOCCOSIS; META ANALYSIS (TOPIC); NASOPHARYNX; NEISSERIA MENINGITIDIS; PNEUMOCOCCAL INFECTION; REVIEW; STREPTOCOCCUS PNEUMONIAE; SYSTEMATIC REVIEW (TOPIC);

CARRIER PROTEINS; CONJUGATE VACCINES; CRM197; DIPHTHERIA TOXOID; HAEMOPHILUS INFLUENZAEPROTEIN D; MENINGOCOCCAL OUTER MEMBRANE PROTEIN COMPLEX; STREPTOCOCCUS PNEUMONIAE; TETANUS TOXOID;

ANTIBODIES, BACTERIAL; ANTIBODY AFFINITY; BACTERIAL PROTEINS; DRUG CARRIERS; HAEMOPHILUS VACCINES; HUMANS; IMMUNITY, HERD; IMMUNOLOGIC MEMORY; MENINGOCOCCAL VACCINES; PNEUMOCOCCAL VACCINES; POLYSACCHARIDES, BACTERIAL; VACCINES, CONJUGATE;

EID: 84893106210     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.26109     Document Type: Review

References (276)

1. Weller PF, Smith AL, Smith D.H., Anderson P. Role of immunity in the clearance of bacteremia due to Haemophilus influenzae. J Infect Dis 1978; 138: 427-36; PMID: 309494; http://dx. (Pubitemid 9032736)
2. Kelly DF, Moxon ER, Pollard AJ. Haemophilus influenzae type b conjugate vaccines. Immunology 2004; 113: 163-74; PMID: 15379976; http://dx.doi.org/10. 1111/j.1365-2567.2004.01971.x (Pubitemid 39312443)
3. Lesinski GB, Westerink MA. Novel vaccine strategies to T-independent antigens. J Microbiol Methods 2001; 47: 135-49; PMID: 11576678; http://dx.doi.org/10.1016/S0167-7012(01)00290-1 (Pubitemid 32910271)
4. Landsteiner K. The specificity of serologic reactions. Cambridge, Mass: Harvard University Press 2013.
5. Avery OT, Goebel WF. CHEMO-IMMUNOLOGICAL STUDIES ON CONJUGATED CARBOHYDRATE-PROTEINS: II. IMMUNOLOGICAL SPECIFICITY OF SYNTHETIC SUGAR-PROTEIN ANTIGENS. J Exp Med 1929; 50: 533-50; PMID: 19869645; http://dx.doi.org/10.1084/ jem.50.4.533
6. Schneerson R, Barrera O, Sutton A., Robbins JB. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med 1980; 152: 361-76; PMID: 6967514; http://dx.doi.org/10.1084/jem.152.2.361 (Pubitemid 10037059)
7. Zahradnik JM, Gordon L. Augmented antibody (Ab) responses in infants administered a new Haemophilus influenzae type b capsular polysaccharide (PRP) diphtheria toxoid conjugate vaccine (PRP-D). Pediatr Res 1984; 18: 289A; http://dx.doi.org/10.1203/00006450-198404001-01178
8. Anderson PW, Pichichero ME, Insel R.A., Betts R., Eby R, Smith DH. Vaccines consisting of periodate-cleaved oligosaccharides from the capsule of Haemophilus influenzae type b coupled to a protein carrier: structural and temporal requirements for priming in the human infant. J Immunol 1986; 137: 1181-6; PMID: 3016088 (Pubitemid 16041100)
9. Marburg S, Jorn D, Tolman RL. Bimolecular Chemistry of Macromolecules: Synthesis of Bacterial Polysaccharide Conjugates with Neisseria me ning itidis Membrane Protein. J Am Chem Soc 1986; 108: 5282-7; http://dx.doi.org/10.1021/ ja00277a037 (Pubitemid 16041644)
10. Giannini G, Rappuoli R, Ratti G. The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197. Nucleic Acids Res 1984; 12: 4063-9; PMID: 6427753; http://dx.doi.org/10.1093/nar/12.10.4063
11. Comvax® [Haemophilus b Conjugate (Meningococcal Protein Conjugate) and Hepatitis B (Recombinant) Vaccine]. Merck & Co, Inc 2001.
12. Menactra Meningococcal. (Groups A, C, Y and W-135) Polysaccharide Diptheria Toxoid Conjugate Vaccine. Sanofi Pasteur 2008.
13. Ruan MR, Akkoyunlu M, Grubb A., Forsgren A. Protein D of Haemophilus influenzae. a novel bacterial surface protein with affinity for human IgD. J Immunol 1990; 145: 3379-84; PMID: 2230124
14. Anderson P, Pichichero ME, Insel RA. Immunogens consisting of oligosaccharides from the capsule of Haemophilus influenzae type b coupled to diphtheria toxoid or the toxin protein CRM197. J Clin Invest 1985; 76: 52-9; PMID: 3874882; http://dx.doi.org/10.1172/JCI111976 (Pubitemid 15240416)
15. Anderson P, Pichichero M, Insel R., Farsad P, Santosham M. Capsular antigens noncovalently or covalently associated with protein as vaccines to Haemophilus influenzae type b: comparison in two-year-old children. J Infect Dis 1985; 152: 634-6; PMID: 3875668; http://dx.doi.org/10.1093/infdis/152.3.634 (Pubitemid 15018701)
16. Anderson P, Pichichero ME, Insel RA. Immunization of 2-month-old infants with protein-coupled oligosaccharides derived from the capsule of Haemophilus influenzae type b. J Pediatr 1985; 107: 346-51; PMID: 3875705; http://dx.doi.org/10.1016/S0022-3476(85)80504-7 (Pubitemid 15240785)
17. Anderson PW, Pichichero ME, Insel R.A., Betts R., Eby R, Smith DH. Vaccines consisting of periodate-cleaved oligosaccharides from the capsule of Haemophilus influenzae type b coupled to a protein carrier: structural and temporal requirements for priming in the human infant. J Immunol 1986; 137: 1181-6; PMID: 3016088 (Pubitemid 16041100)
18. Anderson PW, Pichichero ME, Stein E.C., Porcelli S., Betts RF, Connuck DM, Korones D, Insel R.A., Zahradnik JM, Eby R. Effect of oligosaccharide chain length, exposed terminal group, and hapten loading on the antibody response of human adults and infants to vaccines consisting of Haemophilus influenzae type b capsular antigen unterminally coupled to the diphtheria protein CRM197. J Immunol 1989; 142: 2464-8; PMID: 2784464 (Pubitemid 19098262)
19. Anderson P, Porcelli S, Pichichero ME. Effect of phosphate ester residues on the immunogenicity of CRM197-coupled Haemophilus influenzae type b capsular saccharides in 2-month-old infants. J Infect Dis 1992; 165(Suppl 1): S160-1; PMID: 1588154; http://dx.doi.org/10.1093/infdis/165-Supplement-1-S160
20. Schneerson R, Robbins JB, Parke JC Jr., Bell C., Schlesselman JJ, Sutton A, Wang Z, Schiffman G., Karpas A, Shiloach J. Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates. Infect Immun 1986; 52: 519-28; PMID: 3516876 (Pubitemid 16117810)
21. Claesson BA, Schneerson R, Trollfors B., Lagergård T, Taranger J., Robbins JB. Duration of serum antibodies elicited by Haemophilus influenzae type b capsular polysaccharide alone or conjugated to tetanus toxoid in 18- to 23-month-old children. J Pediatr 1990; 116: 929-31; PMID: 2348298; http://dx.doi.org/10.1016/S0022-3476(05)80655-9 (Pubitemid 20201706)
22. Claesson BA, Schneerson R, Lagergård T, Trollfors B., Taranger J, Johansson J, Bryla D., Robbins JB. Persistence of serum antibodies elicited by Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in infants vaccinated at 3, 5 and 12 months of age. Pediatr Infect Dis J 1991; 10: 560-4; PMID: 1891286; http://dx.doi.org/10.1097/00006454-199108000-00002
23. Einhorn MS, Weinberg GA, Anderson E.L., Granoff PD, Granoff DM. Immunogenicity in infants of Haemophilus influenzae type B polysaccharide in a conjugate vaccine with Neisseria meningitidis outer-membrane protein. Lancet 1986; 2: 299-302; PMID: 2874327; http://dx.doi.org/10.1016/S0140-6736(86)90001-2 (Pubitemid 16069611)
24. Weinberg GA, Einhorn MS, Lenoir A.A., Granoff PD, Granoff DM. Immunologic priming to capsular polysaccharide in infants immunized with Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine. J Pediatr 1987; 111: 22-7; PMID: 3110388; http://dx.doi.org/10.1016/S0022-3476(87)80336-0 (Pubitemid 17092641)
25. Lenoir AA, Granoff PD, Granoff DM. Immunogenicity of Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine in 2- to 6-month-old infants. Pediatrics 1987; 80: 283-7; PMID: 3112729 (Pubitemid 17126808)
26. Lepow ML, Samuelson JS, Gordon LK. Safety and immunogenicity of Haemophilus influenzae type B polysaccharide-diphtheria toxoid conjugate vaccine in adults. J Infect Dis 1984; 150: 402-6; PMID: 6332863; http://dx.doi.org/10. 1093/infdis/150.3.402 (Pubitemid 14037026)
27. Granoff DM, Boies EG, Munson RS Jr. Immunogenicity of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in adults. J Pediatr 1984; 105: 22-7; PMID: 6610736; http://dx.doi.org/10.1016/S0022- 3476(84)80350-9 (Pubitemid 14086263)
28. Lepow ML, Samuelson JS, Gordon LK. Safety and immunogenicity of Haemophilus influenzae type b-polysaccharide diphtheria toxoid conjugate vaccine in infants 9 to 15 months of age. J Pediatr 1985; 106: 185-9; PMID: 3871477; http://dx.doi.org/10.1016/S0022-3476(85)80284-5 (Pubitemid 15130063)
29. Berkowitz CD, Ward JI, Meier K, Hendley J.O., Brunell PA, Barkin RA, Zahradnik JM, Samuelson J, Gordon L. Safety and immunogenicity of Haemophilus influenzae type b polysaccharide and polysaccharide diphtheria toxoid conjugate vaccines in children 15 to 24 months of age. J Pediatr 1987; 110: 509-14; PMID: 3550021; http://dx.doi.org/10.1016/S0022-3476(87)80540-1 (Pubitemid 17049034)
30. Eskola J, Peltola H, Takala A.K., Käyhty H, Hakulinen M., Karanko V, Kela E, Rekola P., Rönnberg PR, Samuelson J.S., et al. Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in infancy. N Engl J Med 1987; 317: 717-22; PMID: 3306379; http://dx.doi.org/ 10.1056/NEJM198709173171201 (Pubitemid 17138201)
31. Eskola J, Käyhty H, Takala A.K., Peltola H., Rönnberg PR, Kela E., Pekkanen E, McVerry PH, Mäkelä PH. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. N Engl J Med 1990; 323: 1381-7; PMID: 2233904; http://dx.doi.org/10.1056/NEJM199011153232004
32. Santosham M, Wolff M, Reid R., Hohenboken M, Bateman M, Goepp J., Cortese M, Sack D, Hill J., Newcomer W, et al. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N Engl J Med 1991; 324: 1767-72; PMID: 1903846; http://dx.doi.org/10.1056/NEJM199106203242503
33. Booy R, Moxon ER, MacFarlane J.A., Mayon-White RT, Slack MP. Efficacy of Haemophilus influenzae type B conjugate vaccine in Oxford region. Lancet 1992; 340: 847; PMID: 1357260; http://dx.doi.org/10.1016/0140-6736(92)92719-V
34. Mulholland K, Hilton S, Adegbola R., Usen S, Oparaugo A, Omosigho C., Weber M, Palmer A, Schneider G., Jobe K, et al. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine [corrected] for prevention of pneumonia and meningitis in Gambian infants. Lancet 1997; 349: 1191-7; PMID: 9130939; http://dx.doi.org/10.1016/S0140-6736(96)09267-7 (Pubitemid 27190041)
35. Peltola H, Eskola J, Käyhty H, Takala A.K., Mäkelä PH. Clinical comparison of the Haemophilus influenzae type B polysaccharide- diphtheria toxoid and the oligosaccharide-CRM197 protein vaccines in infancy. Arch Pediatr Adolesc Med 1994; 148: 620-5; PMID: 8193690; http://dx.doi.org/10. 1001/archpedi.1994.02170060074015 (Pubitemid 24168397)
36. Huebner RE, Nicol M, Mothupi R., Käyhty H, Mbelle N., Khomo E, Klugman KP. Dose response of CRM197 and tetanus toxoid-conjugated Haemophilus influenzae type b vaccines. Vaccine 2004; 23: 802-6; PMID: 15542205; http://dx.doi.org/10.1016/j.vaccine.2004.06.052 (Pubitemid 39473179)
37. Tamm E, Veronese A, Contorni M., Meriste S, Nacci P, Viviani S. Double-blind study comparing the immunogenicity of a licensed DTwPHib-CRM197 conjugate vaccine (Quattvaxem) with three investigational, liquid formulations using lower doses of Hib-CRM197 conjugate. Vaccine 2005; 23: 1715-9; PMID: 15705477; http://dx.doi.org/10.1016/j.vaccine.2004.09.028 (Pubitemid 40215706)
38. Anderson EL, Frey S, Geldmacher K., Radley D, Lee A, Donnelly J., Mendelman PM, Dargan JM, Kaplan KM. Safety, tolerability and immunogenicity of low dose Haemophilus influenzae type b conjugated to the outer membrane protein complex of Neisseria meningitidis group B. Pediatr Infect Dis J 2002; 21: 350-2; PMID: 12075771; http://dx.doi.org/10.1097/00006454-200204000-00019 (Pubitemid 34326878)
39. Kurikka S, Käyhty H, Saarinen L., Rönnberg P, Eskola J., Mäkelä PH. Comparison of five different vaccination schedules with Haemophilus influenzae type b-tetanus toxoid conjugate vaccine. J Pediatr 1996; 128: 524-30; PMID: 8618187; http://dx.doi.org/10.1016/S0022-3476(96)70364-5 (Pubitemid 26114091)
40. Rennels M, King J Jr., Ryall R, Manoff S., Papa T, Weddle A, Froeschle J. Dose escalation, safety and immunogenicity study of a tetravalent meninogococcal polysaccharide diphtheria conjugate vaccine in toddlers. Pediatr Infect Dis J 2002; 21: 978-9; PMID: 12400528; http://dx.doi.org/10.1097/ 00006454-200210000-00019 (Pubitemid 35176163)
41. Silfverdal SA, Hogh B, Bergsaker M.R., Skerlikova H., Lommel P, Borys D, Schuerman L. Immunogenicity of a 2-dose priming and booster vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine. Pediatr Infect Dis J 2009; 28: e276-82; PMID: 20118683; http://dx.doi.org/10.1097/INF.0b013e3181b48ca3
42. McVernon J., Nolan T, Richmond P., Reynolds G, Nissen M, Lambert S.B., Marshall H., Papa T, Rehm C. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers. Pediatr Infect Dis J 2012; 31: e15-23; PMID: 22094636; http://dx.doi.org/10.1097/INF. 0b013e31823e1e34
43. Daum RS, Siber GR, Ballanco G.A., Sood SK. Serum anticapsular antibody response in the first week after immunization of adults and infants with the Haemophilus influenzae type b-Neisseria meningitidis outer membrane protein complex conjugate vaccine. J Infect Dis 1991; 164: 1154-9; PMID: 1955715; http://dx.doi.org/10.1093/infdis/164.6.1154
44. Goldblatt D, Southern J, Ashton L., Richmond P, Burbidge P, Tasevska J., Crowley-Luke A, Andrews N, Morris R., Borrow R, et al. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 2006; 25: 312-9; PMID: 16567982; http://dx.doi.org/10.1097/01.inf.0000207483.60267.e7
45. Griffiths UK, Clark A, Gessner B., Miners A, Sanderson C, Sedyaningsih E.R., Mulholland KE. Dose-specific efficacy of Haemophilus influenzae type b conjugate vaccines: A systematic review and meta-analysis of controlled clinical trials. Epidemiol Infect 2012; 140: 1343-55; PMID: 22583474; http://dx.doi.org/10.1017/S0950268812000957
46. Granoff DM, Anderson EL, Osterholm M.T., Holmes SJ, McHugh JE, Belshe RB, Medley F, Murphy TV. Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants. J Pediatr 1992; 121: 187-94; PMID: 1640282; http://dx.doi.org/10.1016/S0022-3476(05)81186-2
47. Decker MD, Edwards KM, Bradley R, Palmer P. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J Pediatr 1992; 120: 184-9; PMID: 1735812; http://dx.doi.org/10.1016/S0022-3476(05)80424-X
48. Käyhty H., Eskola J, Peltola H., Rönnberg PR, Kela E., Karanko V, Saarinen L. Antibody responses to four Haemophilus influenzae type b conjugate vaccines. Am J Dis Child 1991; 145: 223-7; PMID: 1994693
49. Bulkow LR, Wainwright RB, Letson G.W., Chang SJ, Ward JI. Comparative immunogenicity of four Haemophilus influenzae type b conjugate vaccines in Alaska Native infants. Pediatr Infect Dis J 1993; 12: 484-92; PMID: 8345981; http://dx.doi.org/10.1097/00006454-199306000-00006 (Pubitemid 23173492)
50. Ward J, Brenneman G, Letson G.W., Heyward WL. Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. The Alaska H. influenzae Vaccine Study Group. N Engl J Med 1990; 323: 1393-401; PMID: 2233906; http://dx.doi.org/10.1056/NEJM199011153232006
51. Singleton R, Hammitt L, Hennessy T., Bulkow L, DeByle C, Parkinson A., Cottle TE, Peters H, Butler JC. The Alaska Haemophilus influenzae type b experience: lessons in controlling a vaccine-preventable disease. Pediatrics 2006; 118: e421-9; PMID: 16882783; http://dx.doi.org/10.1542/peds.2006-0287 (Pubitemid 46085381)
52. Gourley TS, Wherry EJ, Masopust D, Ahmed R. Generation and maintenance of immunological memory. Semin Immunol 2004; 16: 323-33; PMID: 15528077; http://dx.doi.org/10.1016/j.smim.2004.08.013 (Pubitemid 39451802)
53. Granoff DM, Lucas AH. Laboratory correlates of protection against Haemophilus influenzae type b disease. Importance of assessment of antibody avidity and immunologic memory. Ann N Y Acad Sci 1995; 754: 278-88; PMID: 7625664; http://dx.doi.org/10.1111/j.1749-6632.1995.tb44461.x
54. Insel RA, Anderson PW. Oligosaccharide-protein conjugate vaccines induce and prime for oligoclonal IgG antibody responses to the Haemophilus influenzae b capsular polysaccharide in human infants. J Exp Med 1986; 163: 262-9; PMID: 3484778; http://dx.doi.org/10.1084/jem.163.2.262 (Pubitemid 16113066)
55. Goldblatt D, Vaz AR, Miller E. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J Infect Dis 1998; 177: 1112-5; PMID: 9534995; http://dx.doi.org/10.1086/517407 (Pubitemid 28155915)
56. Goldblatt D, Richmond P, Millard E., Thornton C, Miller E. The induction of immunologic memory after vaccination with Haemophilus influenzae type b conjugate and acellular pertussis-containing diphtheria, tetanus, and pertussis vaccine combination. J Infect Dis 1999; 180: 538-41; PMID: 10395878; http://dx.doi.org/10.1086/314901 (Pubitemid 30256344)
57. Zepp F, Schmitt HJ, Kaufhold A, Schuind A., Knuf M, Habermehl P, Meyer C., Bogaerts H, Slaoui M, Clemens R. Evidence for induction of polysaccharide specific B-cell-memory in the 1st year of life: plain Haemophilus influenzae type b-PRP (Hib) boosters children primed with a tetanus-conjugate Hib-DTPa-HBV combined vaccine. Eur J Pediatr 1997; 156: 18-24; PMID: 9007484; http://dx.doi.org/10.1007/s004310050544 (Pubitemid 26425772)
58. Granoff DM, Holmes SJ, Osterholm M.T., McHugh JE, Lucas AH, Anderson EL, Belshe R.B., Jacobs JL, Medley F, Murphy TV. Induction of immunologic memory in infants primed with Haemophilus influenzae type b conjugate vaccines. J Infect Dis 1993; 168: 663-71; PMID: 8354908; http://dx.doi.org/10.1093/infdis/168.3.663 (Pubitemid 23254286)
59. Anderson P, Ingram DL, Pichichero M.E., Peter G. A high degree of natural immunologic priming to the capsular polysaccharide may not prevent Haemophilus influenzae type b meningitis. Pediatr Infect Dis J 2000; 19: 589-91; PMID: 10917213; http://dx.doi.org/10.1097/00006454-200007000-00001 (Pubitemid 30469762)
60. Ramsay ME, McVernon J, Andrews N.J., Heath PT, Slack MP. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J Infect Dis 2003; 188: 481-5; PMID: 12898433; http://dx.doi.org/10.1086/376997 (Pubitemid 37011798)
61. McVernon J, Andrews N, Slack M.P., Ramsay ME. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet 2003; 361: 1521-3; PMID: 12737866; http://dx.doi.org/10.1016/ S0140-6736(03)13171-6 (Pubitemid 36566346)
62. Heath PT, Booy R, Azzopardi H.J., Slack MP, Bowen-Morris J, Griffiths H, Ramsay M.E., Deeks JJ, Moxon ER. Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom. JAMA 2000; 284: 2334-40; PMID: 11066183; http://dx.doi.org/10.1001/jama.284.18.2334
63. Pichichero ME, Passador S. Administration of combined diphtheria and tetanus toxoids and pertussis vaccine, hepatitis B vaccine, and Haemophilus influenzae type b (Hib) vaccine to infants and response to a booster dose of Hib conjugate vaccine. Clin Infect Dis 1997; 25: 1378-84; PMID: 9431382; http://dx.doi.org/10.1086/516154 (Pubitemid 28022675)
64. Halperin BA, Morris A, Mackinnon-Cameron D, Mutch J., Langley JM, McNeil SA, Macdougall D, Halperin SA. Kinetics of the antibody response to tetanus-diphtheria-acellular pertussis vaccine in women of childbearing age and postpartum women. Clin Infect Dis 2011; 53: 885-92; PMID: 21946190; http://dx.doi.org/10.1093/cid/cir538
65. Wing JB, Smart L, Borrow R., Findlow J, Findlow H, Heath A.W., Read RC. Kinetics of immune responses to nasal challenge with meningococcal polysaccharide one year after serogroup-C glycoconjugate vaccination. Clin Infect Dis 2011; 52: 1317-23; PMID: 21596673; http://dx.doi.org/10.1093/cid/ cir198
66. Lee YC, Kelly DF, Yu L.M., Slack MP, Booy R, Heath PT, Siegrist C.A., Moxon RE, Pollard AJ. Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody. Clin Infect Dis 2008; 46: 186-92; PMID: 18171249; http://dx.doi.org/10.1086/524668 (Pubitemid 351269156)
67. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 2008; 47: 401-9; PMID: 18558875; http://dx.doi.org/10.1086/589862 (Pubitemid 352009364)
68. Pichichero ME. Booster vaccinations: can immunologic memory outpace disease pathogenesis? Pediatrics 2009; 124: 1633-41; PMID: 19933727; http://dx.doi.org/10.1542/peds.2008-3645
69. Auckland C, Gray S, Borrow R., Andrews N, Goldblatt D, Ramsay M., Miller E. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis 2006; 194: 1745-52; PMID: 17109348; http://dx.doi.org/10.1086/509619 (Pubitemid 44902007)
70. Perrett KP, Winter AP, Kibwana E, Jin C., John TM, Yu LM, Borrow R, Curtis N., Pollard AJ. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: A phase 4 clinical trial. Clin Infect Dis 2010; 50: 1601-10; PMID: 20459323; http://dx.doi.org/10.1086/652765
71. Blanchard Rohner G., Snape MD, Kelly D.F., John T., Morant A, Yu LM, Borkowski A, Ceddia F., Borrow R, Siegrist CA, et al. The magnitude of the antibody and memory B cell responses during priming with a protein- polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response. J Immunol 2008; 180: 2165-73; PMID: 18250423
72. Borrow R, Andrews N, Findlow H., Waight P, Southern J, Crowley-Luke A, Stapley L., England A, Findlow J, Miller E. Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccine Immunol 2010; 17: 154-9; PMID: 19906895; http://dx.doi.org/10.1128/CVI. 00384-09
73. Gill CJ, Baxter R, Anemona A., Ciavarro G, Dull P. Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents. Hum Vac cin 2010; 6: 881-7; PMID: 21339701; http://dx.doi.org/10. 4161/hv.6.11.12849
74. de Whalley P.C., Snape MD, Kelly D.F., Banner C., Lewis S, Diggle L, John T.M., Yu LM, Omar O, Borkowski A, et al. Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine. Pediatr Infect Dis J 2011; 30: e203-8; PMID: 21673612; http://dx.doi.org/10.1097/INF. 0b013e318224fb14
75. Tregnaghi M, Zambrano B, Santos-Lima E. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants. Pediatr Infect Dis J 2012; 31: e24-30; PMID: 22157567; http://dx.doi.org/10.1097/INF.0b013e318242460a
76. Booy R, Richmond P, Nolan T., McVernon J, Marshall H, Nissen M., Reynolds G, Ziegler JB, Stoney T, Heron L., et al. Three-year antibody persistence and safety after a single dose of combined haemophilus influenzae type b (Hib)-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in Hib-primed toddlers. Pediatr Infect Dis J 2013; 32: 169-74; PMID: 23080288; http://dx.doi.org/10.1097/INF.0b013e3182787bff
77. Anderson EL, Kennedy DJ, Geldmacher K.M., Donnelly J., Mendelman PM. Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants. J Pediatr 1996; 128: 649-53; PMID: 8627437; http://dx.doi.org/10.1016/S0022- 3476(96)80130-2 (Pubitemid 26137723)
78. Dagan R, Melamed R, Zamir O., Leroy O. Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens. Pediatr Infect Dis J 1997; 16: 1053-9; PMID: 9384339; http://dx.doi.org/10.1097/00006454-199711000- 00010 (Pubitemid 27494963)
79. Ahman H, Käyhty H, Lehtonen H., Leroy O, Froeschle J, Eskola J. Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory. Pediatr Infect Dis J 1998; 17: 211-6; PMID: 9535248; http://dx.doi.org/10.1097/ 00006454-199803000-00008 (Pubitemid 28146062)
80. Rennels MB, Edwards KM, Keyserling H.L., Reisinger KS, Hogerman DA, Madore DV, Chang I, Paradiso P.R., Malinoski FJ, Kimura A. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics 1998; 101: 604-11; PMID: 9521941; http://dx.doi.org/10.1542/peds.101.4.604 (Pubitemid 28180141)
81. Knuf M, Pankow-Culot H, Grunert D., Rapp M, Panzer F, Köllges R, Fanic A., Habib A, Borys D, Dieussaert I., et al. Induction of immunologic memory following primary vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in infants. Pediatr Infect Dis J 2012; 31: e31-6; PMID: 21909049; http://dx.doi.org/10.1097/INF. 0b013e3182323ac2
82. Leach A, Twumasi PA, Kumah S, Banya W.S., Jaffar S., Forrest BD, Granoff DM, LiButti DE, Carlone G.M., Pais LB, et al. Induction of immunologic memory in Gambian children by vaccination in infancy with a group a plus group C meningococcal polysaccharide-protein conjugate vaccine. J Infect Dis 1997; 175: 200-4; PMID: 8985221; http://dx.doi.org/10.1093/infdis/175.1.200 (Pubitemid 27020849)
83. MacDonald NE, Halperin SA, Law B.J., Forrest B., Danzig LE, Granoff DM. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: A randomized controlled trial. JAMA 1998; 280: 1685-9; PMID: 9832000; http://dx.doi.org/10.1001/jama.280.19.1685 (Pubitemid 28532992)
84. Richmond P, Borrow R, Miller E., Clark S, Sadler F, Fox A., Begg N, Morris R, Cartwright K. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis 1999; 179: 1569-72; PMID: 10228085; http://dx.doi.org/10.1086/314753 (Pubitemid 29246613)
85. MacLennan JM, Shackley F, Heath P.T., Deeks JJ, Flamank C, Herbert M, Griffiths H., Hatzmann E, Goilav C, Moxon ER. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: A randomized controlled trial. JAMA 2000; 283: 2795-801; PMID: 10838647; http://dx.doi.org/10.1001/jama.283.21.2795 (Pubitemid 30387823)
86. Richmond P, Borrow R, Goldblatt D., Findlow J, Martin S, Morris R., Cartwright K, Miller E. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis 2001; 183: 160-3; PMID: 11078484; http://dx.doi.org/10.1086/317646 (Pubitemid 32043057)
87. MacLennan J, Obaro S, Deeks J., Lake D, Elie C, Carlone G., Moxon ER, Greenwood B. Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy. J Infect Dis 2001; 183: 97-104; PMID: 11087205; http://dx.doi.org/10.1086/317667 (Pubitemid 32043046)
88. Borrow R, Goldblatt D, Andrews N., Southern J, Ashton L, Deane S., Morris R, Cartwright K, Miller E. Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United kingdom. J Infect Dis 2002; 186: 1353-7; PMID: 12402208; http://dx.doi.org/10.1086/344324 (Pubitemid 35193017)
89. McVernon J., Maclennan J, Buttery J., Oster P, Danzig L, Moxon ER. Safety and immunogenicity of meningococcus serogroup C conjugate vaccine administered as a primary or booster vaccination to healthy four-year-old children. Pediatr Infect Dis J 2002; 21: 747-53; PMID: 12192163; http://dx.doi.org/10.1097/ 00006454-200208000-00010
90. McVernon J, MacLennan J, Pollard A.J., Oster P., Wakefield MJ, Danzig L, Moxon ER. Immunologic memory with no detectable bactericidal antibody response to a first dose of meningococcal serogroup C conjugate vaccine at four years. Pediatr Infect Dis J 2003; 22: 659-61; PMID: 12886896; http://dx.doi.org/10. 1097/01.inf.0000076386.52719.b3 (Pubitemid 36900217)
91. Borrow R, Goldblatt D, Finn A., Southern J, Ashton L, Andrews N., Lal G, Riley C, Rahim R., Cartwright K, et al. Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom. Infect Immun 2003; 71: 5549-55; PMID: 14500473; http://dx.doi.org/10.1128/IAI.71.10.5549-5555.2003 (Pubitemid 37205605)
92. Keyserling H, Papa T, Koranyi K., Ryall R, Bassily E, Bybel M.J., Sullivan K., Gilmet G, Reinhardt A. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A,C,Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med 2005; 159: 907-13; PMID: 16203934; http://dx.doi.org/10.1001/archpedi.159. 10.907 (Pubitemid 41423328)
93. Pichichero M, Papa T, Blatter M., Mitchell D, Kratz R, Sneed J., Bassily E, Casey J, Gilmet G. Immune memory in children previously vaccinated with an experimental quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine. Pediatr Infect Dis J 2006; 25: 995-1000; PMID: 17072120; http://dx.doi.org/10.1097/01.inf.0000243215.46312.4a (Pubitemid 44657807)
94. Pichichero ME, Sommerfelt AE, Steinhoff M.C., Insel RA. Breast milk antibody to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1980; 142: 694-8; PMID: 6970233; http://dx.doi.org/10.1093/infdis/ 142.5.694 (Pubitemid 11138421)
95. Pichichero ME, Hall CB, Insel RA. A mucosal antibody response following systemic Haemophilus influenzae type B infection in children. J Clin Invest 1981; 67: 1482-9; PMID: 6971877; http://dx.doi.org/10.1172/JCI110178 (Pubitemid 11099364)
96. Pichichero ME, Insel RA. Relationship between naturally occurring human mucosal and serum antibody to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1982; 146: 243-8; PMID: 6980956; http://dx.doi.org/10.1093/infdis/146.2.243 (Pubitemid 12009790)
97. Pichichero ME, Insel RA. Mucosal antibody response to parenteral vaccination with Haemophilus influenzae type b capsule. J Allergy Clin Immunol 1983; 72: 481-6; PMID: 6605372; http://dx.doi.org/10.1016/0091-6749(83)90585-7 (Pubitemid 14206015)
98. Nieminen T, Käyhty H, Virolainen A., Eskola J. Circulating antibody secreting cell response to parenteral pneumococcal vaccines as an indicator of a salivary IgA antibody response. Vaccine 1998; 16: 313-9; PMID: 9607048; http://dx.doi.org/10.1016/S0264-410X(97)00162-X (Pubitemid 27521016)
99. Nieminen T, Eskola J, Käyhty H. Pneumococcal conjugate vaccination in adults: circulating antibody secreting cell response and humoral antibody responses in saliva and in serum. Vaccine 1998; 16: 630-6; PMID: 9569475; http://dx.doi.org/10.1016/S0264-410X(97)00235-1 (Pubitemid 28112561)
100. Nieminen T, Käyhty H, Leroy O., Eskola J. Pneumococcal conjugate vaccination in toddlers: mucosal antibody response measured as circulating antibody-secreting cells and as salivary antibodies. Pediatr Infect Dis J 1999; 18: 764-72; PMID: 10493335; http://dx.doi.org/10.1097/00006454-199909000-00005 (Pubitemid 29428530)
101. Korkeila M, Lehtonen H, Ahman H., Leroy O, Eskola J, Käyhty H. Salivary anti-capsular antibodies in infants and children immunised with Streptococcus pneumoniae capsular polysaccharides conjugated to diphtheria or tetanus toxoid. Vaccine 2000; 18: 1218-26; PMID: 10649623; http://dx.doi.org/10. 1016/S0264-410X(99)00393-X (Pubitemid 30001836)
102. Choo S, Zhang Q, Seymour L., Akhtar S, Finn A. Primary and booster salivary antibody responses to a 7-valent pneumococcal conjugate vaccine in infants. J Infect Dis 2000; 182: 1260-3; PMID: 10979930; http://dx.doi.org/10. 1086/315834
103. Nurkka A, Ahman H, Korkeila M., Jäntti V, Käyhty H, Eskola J. Serum and salivary anti-capsular antibodies in infants and children immunized with the heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2001; 20: 25-33; PMID: 11176563; http://dx.doi.org/10.1097/00006454-200101000-00006 (Pubitemid 32066172)
104. Nurkka A, Ahman H, Yaich M., Eskola J, Käyhty H. Serum and salivary anti-capsular antibodies in infants and children vaccinated with octavalent pneumococcal conjugate vaccines, PncD and PncT. Vaccine 2001; 20: 194-201; PMID: 11567764; http://dx.doi.org/10.1016/S0264-410X(01)00250-X (Pubitemid 32905332)
105. Finn A, Zhang Q, Seymour L., Fasching C, Pettitt E, Janoff EN. Induction of functional secretory IgA responses in breast milk, by pneumococcal capsular polysaccharides. J Infect Dis 2002; 186: 1422-9; PMID: 12404157; http://dx.doi.org/10.1086/344356 (Pubitemid 35286109)
106. Takala AK, Eskola J, Leinonen M., Käyhty H, Nissinen A., Pekkanen E, Mäkelä PH. Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine. J Infect Dis 1991; 164: 982-6; PMID: 1940479; http://dx.doi.org/10.1093/infdis/ 164.5.982
107. Kauppi-Korkeila M., van Alphen L, Madore D, Saarinen L., Käyhty H. Mechanism of antibody-mediated reduction of nasopharyngeal colonization by Haemophilus influenzae type b studied in an infant rat model. J Infect Dis 1996; 174: 1337-40; PMID: 8940229; http://dx.doi.org/10.1093/infdis/174.6.1337 (Pubitemid 26393917)
108. Takala AK, Santosham M, Almeido-Hill J, Wolff M., Newcomer W, Reid R, Käyhty H, Esko E., Mäkelä PH. Vaccination with Haemophilus influenzae type b meningococcal protein conjugate vaccine reduces oropharyngeal carriage of Haemophilus influenzae type b among American Indian children. Pediatr Infect Dis J 1993; 12: 593-9; PMID: 8346004; http://dx.doi.org/10.1097/ 00006454-199307000-00010 (Pubitemid 23199516)
109. Fernandez J, Levine OS, Sanchez J, Balter S., LaClaire L, Feris J, Romero-Steiner S. Prevention of Haemophilus influenzae type b colonization by vaccination: correlation with serum anti-capsular IgG concentration. J Infect Dis 2000; 182: 1553-6; PMID: 11023481; http://dx.doi.org/10.1086/315870
110. Heath PT, McVernon J. The UK Hib vaccine experience. Arch Dis Child 2002; 86: 396-9; PMID: 12023165; http://dx.doi.org/10.1136/adc.86.6.396 (Pubitemid 34596646)
111. Moulton LH, Chung S, Croll J., Reid R, Weatherholtz RC, Santosham M. Estimation of the indirect effect of Haemophilus influenzae type b conjugate vaccine in an American Indian population. Int J Epidemiol 2000; 29: 753-6; PMID: 10922355; http://dx.doi.org/10.1093/ije/29.4.753 (Pubitemid 30612244)
112. Käyhty H., Peltola H, Karanko V., Mäkelä PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983; 147: 1100; PMID: 6602191; http://dx.doi.org/10.1093/infdis/147.6.1100 (Pubitemid 13068358)
113. Dagan R, Givon-Lavi N, Fraser D., Lipsitch M, Siber GR, Kohberger R. Serum serotype-specific pneumococcal anticapsular immunoglobulin g concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus. J Infect Dis 2005; 192: 367-76; PMID: 15995949; http://dx.doi.org/10.1086/431679 (Pubitemid 41023114)
114. Dagan R, Melamed R, Muallem M., Piglansky L, Greenberg D, Abramson O., Mendelman PM, Bohidar N, Yagupsky P. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J Infect Dis 1996; 174: 1271-8; PMID: 8940218; http://dx.doi.org/10.1093/infdis/174.6.1271 (Pubitemid 26393906)
115. Millar EV, O'Brien KL, Bronsdon MA, Madore D, Hackell J.G., Reid R., Santosham M. Anticapsular serum antibody concentration and protection against pneumococcal colonization among children vaccinated with 7-valent pneumococcal conjugate vaccine. Clin Infect Dis 2007; 44: 1173-9; PMID: 17407035; http://dx.doi.org/10.1086/513199 (Pubitemid 46651241)
116. Dagan R, Muallem M, Melamed R., Leroy O, Yagupsky P. Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid. Pediatr Infect Dis J 1997; 16: 1060-4; PMID: 9384340; http://dx.doi.org/10.1097/00006454-199711000-00011 (Pubitemid 27494964)
117. Mbelle N, Huebner RE, Wasas A.D., Kimura A., Chang I, Klugman KP. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis 1999; 180: 1171-6; PMID: 10479145; http://dx.doi.org/10.1086/315009 (Pubitemid 30070201)
118. Dagan R, Givon-Lavi N, Zamir O., Sikuler-Cohen M, Guy L, Janco J., Yagupsky P, Fraser D. Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J Infect Dis 2002; 185: 927-36; PMID: 11920317; http://dx.doi.org/10.1086/339525 (Pubitemid 34274436)
119. Givon-Lavi N., Fraser D, Dagan R. Vac cination of day-care center attendees reduces carriage of Streptococcus pneumoniae among their younger siblings. Pediatr Infect Dis J 2003; 22: 524-32; PMID: 12799509; http://dx.doi.org/10.1097/01.inf.0000069760.65826.f2
120. Dagan R, Givon-Lavi N, Zamir O., Fraser D. Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers. Pediatr Infect Dis J 2003; 22: 532-40; PMID: 12799510; http://dx.doi.org/10.1097/01.inf.0000069761.11093.c3
121. Moore MR, Hyde TB, Hennessy T.W., Parks DJ, Reasonover AL, Harker-Jones M, Gove J, Bruden D.L., Rudolph K., Parkinson A, et al. Impact of a conjugate vaccine on community-wide carriage of nonsusceptible Streptococcus pneumoniae in Alaska. J Infect Dis 2004; 190: 2031-8; PMID: 15529269; http://dx.doi.org/10. 1086/425422 (Pubitemid 39564710)
122. Ghaffar F, Barton T, Lozano J., Muniz LS, Hicks P, Gan V, Ahmad N., McCracken GH Jr. Effect of the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life. Clin Infect Dis 2004; 39: 930-8; PMID: 15472842; http://dx.doi.org/10. 1086/423379 (Pubitemid 39313446)
123. Pelton SI, Loughlin AM, Marchant CD. Seven valent pneumococcal conjugate vaccine immunization in two Boston communities: changes in serotypes and antimicrobial susceptibility among Streptococcus pneumoniae isolates. Pediatr Infect Dis J 2004; 23: 1015-22; PMID: 15545856; http://dx.doi.org/10.1097/01. inf.0000143645.58215.f0 (Pubitemid 40824291)
124. Huang SS, Platt R, Rifas-Shiman SL, Pelton S.I., Goldmann D., Finkelstein JA. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics 2005; 116: e408-13; PMID: 16140686; http://dx.doi.org/10.1542/peds.2004-2338 (Pubitemid 44336655)
125. Jones VF, Harrison C, Stout G.G., Hopkins J. Nasopharyngeal colonization with heptavalent pneumococcal conjugate vaccine serotypes of Streptococcus pneumoniae with prolonged vaccine dosing intervals. Pediatr Infect Dis J 2005; 24: 969-73; PMID: 16282931; http://dx.doi.org/10.1097/01.inf.0000187030.83080.8a (Pubitemid 41689599)
126. Hammitt LL, Bruden DL, Butler J.C., Baggett HC, Hurlburt DA, Reasonover A, Hennessy TW. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J Infect Dis 2006; 193: 1487-94; PMID: 16652275; http://dx.doi.org/10. 1086/503805 (Pubitemid 43794576)
127. Cohen R, Levy C, de La Rocque F, Gelbert N, Wollner A., Fritzell B, Bonnet E, Tetelboum R., Varon E. Impact of pneumococcal conjugate vaccine and of reduction of antibiotic use on nasopharyngeal carriage of nonsusceptible pneumococci in children with acute otitis media. Pediatr Infect Dis J 2006; 25: 1001-7; PMID: 17072121; http://dx.doi.org/10.1097/01.inf.0000243163.85163.a8 (Pubitemid 44657808)
128. Dunais B, Bruno P, Carsenti-Dellamonica H, Touboul P., Dellamonica P, Pradier C. Trends in nasopharyngeal carriage of Streptococcus pneumoniae among children attending daycare centers in southeastern France from 1999 to 2006. Pediatr Infect Dis J 2008; 27: 1033-5; PMID: 18955896; http://dx.doi.org/10. 1097/INF.0b013e31817bb8cf
129. Millar EV, Watt JP, Bronsdon M.A., Dallas J., Reid R, Santosham M, O'Brien KL. Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members. Clin Infect Dis 2008; 47: 989-96; PMID: 18781875; http://dx.doi.org/10.1086/591966
130. Cheung YB, Zaman SM, Nsekpong E.D., Van Beneden CA, Adegbola RA, Greenwood B, Cutts FT. Nasopharyngeal carriage of Streptococcus pneumoniae in Gambian children who participated in a 9-valent pneumococcal conjugate vaccine trial and in their younger siblings. Pediatr Infect Dis J 2009; 28: 990-5; PMID: 19536041; http://dx.doi.org/10.1097/INF.0b013e3181a78185
131. Huang SS, Hinrichsen VL, Stevenson A.E., Rifas-Shiman SL, Kleinman K, Pelton S.I., Lipsitch M., Hanage WP, Lee GM, Finkelstein JA. Continued impact of pneumococcal conjugate vaccine on carriage in young children. Pediatrics 2009; 124: e1-11; PMID: 19564254; http://dx.doi.org/10.1542/peds.2008-3099
132. Spijkerman J, van Gils EJ, Veenhoven RH, Hak E, Yzerman EP, van der Ende A, Wijmenga-Monsuur AJ, van den Dobbelsteen GP, Sanders EA. Carriage of Streptococcus pneumoniae 3 years after start of vaccination program, the Netherlands. Emerg Infect Dis 2011; 17: 584-91; PMID: 21470445
133. Haber M, Barskey A, Baughman W., Barker L, Whitney CG, Shaw K.M., Orenstein W., Stephens DS. Herd immunity and pneumococcal conjugate vaccine: A quantitative model. Vaccine 2007; 25: 5390-8; PMID: 17583392; http://dx.doi.org/10.1016/j.vaccine.2007.04.088 (Pubitemid 46977530)
134. Cohen R, Levy C, Bingen E., Koskas M, Nave I, Varon E. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr Infect Dis J 2012; 31: 297-301; PMID: 22330166; http://dx.doi.org/10.1097/INF.0b013e318247ef84
135. De Wals P., Deceuninck G, Boulianne N., De Serres G. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine. JAMA 2004; 292: 2491-4; PMID: 15562128; http://dx.doi.org/10.1001/jama.292.20. 2491 (Pubitemid 39552674)
136. Trotter CL, Andrews NJ, Kaczmarski E.B., Miller E., Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004; 364: 365-7; PMID: 15276396; http://dx.doi.org/10. 1016/S0140-6736(04)16725-1 (Pubitemid 38970013)
137. Ramsay ME, Andrews NJ, Trotter C.L., Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003; 326: 365-6; PMID: 12586669; http://dx.doi.org/10. 1136/bmj.326.7385.365 (Pubitemid 36241472)
138. Maiden MC, Stuart JM; UK Meningococcal Carraige Group. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002; 359: 1829-31; PMID: 12044380; http://dx.doi.org/10. 1016/S0140-6736(02)08679-8 (Pubitemid 34607060)
139. Prymula R, Hanovcova I, Splino M., Kriz P, Motlova J, Lebedova V., Lommel P, Kaliskova E, Pascal T., Borys D, et al. Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage. Vac cine 2011; 29: 1959-67; PMID: 21215830; http://dx.doi.org/10.1016/j.vaccine.2010.12.086
140. van den Bergh MR, Spijkerman J, Swinnen K.M., François NA, Pascal T.G., Borys D., Schuerman L, Ijzerman EP, Bruin J.P., van der Ende A, et al. Effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine on nasopharyngeal bacterial colonization in young children: A randomized controlled trial. Clin Infect Dis 2013; 56: e30-9; PMID: 23118268; http://dx.doi.org/10.1093/cid/cis922
141. Schlesinger Y, Granoff DM; The Vaccine Study Group. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. JAMA 1992; 267: 1489-94; PMID: 1538539; http://dx.doi.org/10.1001/jama.1992.03480110065035
142. Lucas AH, Granoff DM. Functional differences in idiotypically defined IgG1 anti-polysaccharide antibodies elicited by vaccination with Haemophilus influenzae type B polysaccharide-protein conjugates. J Immunol 1995; 154: 4195-202; PMID: 7706754
143. Granoff DM, Harris SL. Protective activity of group C anticapsular antibodies elicited in two-year-olds by an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine. Pediatr Infect Dis J 2004; 23: 490-7; PMID: 15194828; http://dx.doi.org/10.1097/01.inf.0000129686. 12470.e6 (Pubitemid 38802291)
144. Siskind GW, Benacerraf B. Cell selection by antigen in the immune response. Adv Immunol 1969; 10: 1-50; PMID: 4900673; http://dx.doi.org/10.1016/ S0065-2776(08)60414-9
145. Denoël P.A., Goldblatt D, de Vleeschauwer I, Jacquet JM, Pichichero M.E., Poolman JT. Quality of the Haemophilus influenzae type b (Hib) antibody response induced by diphtheria-tetanus-acellular pertussis/Hib combination vaccines. Clin Vaccine Immunol 2007; 14: 1362-9; PMID: 17699836; http://dx.doi.org/10.1128/CVI.00154-07 (Pubitemid 350012980)
146. Usinger WR, Lucas AH. Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides. Infect Immun 1999; 67: 2366-70; PMID: 10225896 (Pubitemid 29200494)
147. Anttila M, Eskola J, Ahman H., Käyhty H. Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood. Vac cine 1999; 17: 1970-7; PMID: 10217596; http://dx.doi.org/10.1016/ S0264-410X(98)00458-7 (Pubitemid 29172367)
148. Ekström N., Väkeväinen M, Verho J, Kilpi T., Käyhty H. Functional antibodies elicited by two heptavalent pneumococcal conjugate vaccines in the Finnish Otitis Media Vaccine Trial. Infect Immun 2007; 75: 1794-800; PMID: 17261612; http://dx.doi.org/10.1128/IAI.01673-06 (Pubitemid 46559447)
149. Fairley CK, Begg N, Borrow R., Fox AJ, Jones DM, Cartwright K. Conjugate meningococcal serogroup a and C vaccine: reactogenicity and immunogenicity in United Kingdom infants. J Infect Dis 1996; 174: 1360-3; PMID: 8940235; http://dx.doi.org/10.1093/infdis/174.6.1360 (Pubitemid 26393923)
150. Campagne G, Garba A, Fabre P., Schuchat A, Ryall R, Boulanger D., Bybel M, Carlone G, Briantais P., Ivanoff B, et al. Safety and immunogenicity of three doses of a Neisseria meningitidis a + C diphtheria conjugate vaccine in infants from Niger. Pediatr Infect Dis J 2000; 19: 144-50; PMID: 10694002; http://dx.doi.org/10.1097/00006454-200002000-00013 (Pubitemid 30111411)
151. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: A success story. Vacci ne 2001; 20(Suppl 1): S58-67; PMID: 11587814; http://dx.doi.org/10.1016/S0264-410X(01)00299-7 (Pubitemid 32925012)
152. Ramsay ME, Andrews N, Kaczmarski E.B., Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 2001; 357: 195-6; PMID: 11213098; http://dx.doi.org/10.1016/ S0140-6736(00)03594-7 (Pubitemid 32108093)
153. Zhang Q, Lakshman R, Burkinshaw R., Choo S, Everard J, Akhtar S., Finn A. Primary and booster mucosal immune responses to meningococcal group a and C conjugate and polysaccharide vaccines administered to university students in the United Kingdom. Infect Immun 2001; 69: 4337-41; PMID: 11401971; http://dx.doi.org/10.1128/IAI.69.7.4337-4341.2001 (Pubitemid 32574430)
154. Rennels MB, Edwards KM, Keyserling H.L., Reisinger K., Blatter MM, Quataert SA, Madore DV, Chang I, Malinoski F.J., Hackell JG, et al. Safety and immunogenicity of four doses of Neisseria meningitidis group C vaccine conjugated to CRM197 in United States infants. Pediatr Infect Dis J 2001; 20: 153-9; PMID: 11224833; http://dx.doi.org/10.1097/00006454-200102000-00007 (Pubitemid 32151937)
155. Joseph H, Ryall R, Bybel M., Papa T, MacLennan J, Buttery J., Borrow R. Immunogenicity and immunological priming of the serogroup a portion of a bivalent meningococcal A/C conjugate vaccine in 2-year-old children. J Infect Dis 2003; 187: 1142-6; PMID: 12660929; http://dx.doi.org/10.1086/368358 (Pubitemid 36399356)
156. De Wals P., Deceuninck G, De Serres G, Boivin JF, Duval B, Remis R., Massé R. Effectiveness of serogroup C meningococcal polysaccharide vaccine: results from a case-control study in Quebec. Clin Infect Dis 2005; 40: 1116-22; PMID: 15791510; http://dx.doi.org/10.1086/428729 (Pubitemid 40490235)
157. Gray SJ, Trotter CL, Ramsay M.E., Guiver M., Fox AJ, Borrow R, Mallard RH, Kaczmarski EB; Meningococcal Reference Unit. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit. J Med Microbiol 2006; 55: 887-96; PMID: 16772416; http://dx.doi.org/10.1099/jmm.0.46288-0 (Pubitemid 43974695)
158. de Greeff S.C., de Melker HE, Spanjaard L, Schouls LM, van Derende A. Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands. Pediatr Infect Dis J 2006; 25: 79-80; PMID: 16395110; http://dx.doi.org/10.1097/01.inf.0000195594.41449.c6 (Pubitemid 43361483)
159. Snape MD, Kelly DF, Salt P, Green S., Snowden C, Diggle L, Borkowski A., Yu LM, Moxon ER, Pollard AJ. Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization. Clin Infect Dis 2006; 43: 1387-94; PMID: 17083009; http://dx.doi.org/10.1086/508776 (Pubitemid 44845637)
160. Trot ter C.L., Chandra M, Cano R., Larrauri A, Ramsay ME, Brehony C, Jolley K.A., Maiden MC, Heuberger S, Frosch M. A surveillance network for meningococcal disease in Europe. FEMS Microbiol Rev 2007; 31: 27-36; PMID: 17168995; http://dx.doi.org/10.1111/j.1574-6976.2006.00060.x (Pubitemid 46058817)
161. Kshirsagar N, Mur N, Thatte U., Gogtay N, Viviani S, Préziosi MP, Elie C., Findlow H, Carlone G, Borrow R., et al. Safety, immunogenicity, and antibody persistence of a new meningococcal group a conjugate vaccine in healthy Indian adults. Vaccine 2007; 25(Suppl 1): A101-7; PMID: 17532101; http://dx.doi.org/10.1016/j.vaccine.2007.04.050 (Pubitemid 47208600)
162. Maiden MC, Ibarz-Pavón AB, Urwin R, Gray S.J., Andrews NJ, Clarke SC, Walker AM, Evans MR, Kroll JS, Neal KR, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008; 197: 737-43; PMID: 18271745; http://dx.doi.org/10.1086/527401 (Pubitemid 351364476)
163. Bettinger JA, Scheifele DW, Le Saux N, Halperin SA, Vaudry W, Tsang R; Canadian Immunization Monitoring Program, Active (IMPACT). The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada. Pediatr Infect Dis J 2009; 28: 220-4; PMID: 19209096; http://dx.doi.org/10.1097/ INF.0b013e31819040e7
164. De Wals P, Deceuninck G, Lefebvre B, Boulianne N, De Serres G. Effectiveness of serogroup C meningococcal conjugate vaccine: A 7-year follow-up in Quebec, Canada. Pediatr Infect Dis J 2011; 30: 566-9; PMID: 21326136; http://dx.doi.org/10.1097/INF.0b013e31820e8638
165. O'Brien K.L., Steinhoff MC, Edwards K, Keyserling H., Thoms ML, Madore D. Immunologic priming of young children by pneumococcal glycoprotein conjugate, but not polysaccharide, vaccines. Pediatr Infect Dis J 1996; 15: 425-30; PMID: 8724065; http://dx.doi.org/10.1097/00006454-199605000-00009 (Pubitemid 26151213)
166. Shelly MA, Jacoby H, Riley G.J., Graves BT, Pichichero M, Treanor JJ. Comparison of pneumococcal polysaccharide and CRM197-conjugated pneumococcal oligosaccharide vaccines in young and elderly adults. Infect Immun 1997; 65: 242-7; PMID: 8975918 (Pubitemid 27010311)
167. Pichichero ME, Shelly MA, Treanor JJ. Evaluation of a pentavalent conjugated pneumococcal vaccine in toddlers. Pediatr Infect Dis J 1997; 16: 72-4; PMID: 9002106; http://dx.doi.org/10.1097/00006454-199701000-00016 (Pubitemid 27063116)
168. Pichichero ME, Porcelli S, Treanor J, Anderson P. Serum antibody responses of weanling mice and two-year-old children to pneumococcal-type 6A-protein conjugate vaccines of differing saccharide chain lengths. Vaccine 1998; 16: 83-91; PMID: 9607014; http://dx.doi.org/10.1016/S0264-410X(97)00146-1 (Pubitemid 27504809)
169. Käyhty H., Ahman H, Rönnberg PR, Tillikainen R., Eskola J. Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children. J Infect Dis 1995; 172: 1273-8; PMID: 7594664; http://dx.doi.org/10.1093/infdis/172.5.1273
170. Ahman H, Käyhty H, Tamminen P., Vuorela A, Malinoski F, Eskola J. Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants. Pediatr Infect Dis J 1996; 15: 134-9; PMID: 8822286; http://dx.doi.org/10.1097/00006454- 199602000-00009 (Pubitemid 26066877)
171. Daum RS, Hogerman D, Rennels M.B., Bewley K., Malinoski F, Rothstein E, Reisinger K., Block S, Keyserling H, Steinhoff M. Infant immunization with pneumococcal CRM197 vaccines: effect of saccharide size on immunogenicity and interactions with simultaneously administered vaccines. J Infect Dis 1997; 176: 445-55; PMID: 9237711; http://dx.doi.org/10.1086/514063 (Pubitemid 27328768)
172. Shinefield HR, Black S, Ray P., Chang I, Lewis N, Fireman B., Hackell J, Paradiso PR, Siber G, Kohberger R., et al. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 1999; 18: 757-63; PMID: 10493334; http://dx.doi.org/10. 1097/00006454-199909000-00004 (Pubitemid 29428529)
173. Black S, Shinefield H, Fireman B., Lewis E, Ray P, Hansen J.R., Elvin L., Ensor KM, Hackell J, Siber G, et al.; Northern California Kaiser Permanente Vaccine Study Center Group. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000; 19: 187-95; PMID: 10749457; http://dx.doi.org/10.1097/00006454-200003000-00003 (Pubitemid 30167436)
174. Choo S, Seymour L, Morris R., Quataert S, Lockhart S, Cartwright K., Finn A. Immunogenicity and reactogenicity of a pneumococcal conjugate vaccine administered combined with a haemophilus influenzae type B conjugate vaccine in United Kingdom infants. Pediatr Infect Dis J 2000; 19: 854-62; PMID: 11001109; http://dx.doi.org/10.1097/00006454-200009000-00009
175. Schmitt HJ, Faber J, Lorenz I., Schmöle-Thoma B, Ahlers N. The safety, reactogenicity and immunogenicity of a 7-valent pneumococcal conjugate vaccine (7VPnC) concurrently administered with a combination DTaP-IPV-Hib vaccine. Vaccine 2003; 21: 3653-62; PMID: 12922095; http://dx.doi.org/10.1016/ S0264-410X(03)00389-X (Pubitemid 37338190)
176. Käyhty H., Ahman H, Eriksson K., Sörberg M, Nilsson L. Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age. Pediatr Infect Dis J 2005; 24: 108-14; PMID: 15702037; http://dx.doi.org/10.1097/01.inf.0000151022.92222.be (Pubitemid 40250767)
177. Bryant KA, Block SL, Baker S.A., Gruber WC, Scott DA; PCV13 Infant Study Group. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics 2010; 125: 866-75; PMID: 20435707; http://dx.doi.org/10.1542/peds. 2009-1405
178. Kieninger DM, Kueper K, Steul K., Juergens C, Ahlers N, Baker S., Jansen KU, Devlin C, Gruber WC, Emini E.A., et al.; 006 study group. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vac cine 2010; 28: 4192-203; PMID: 20417262; http://dx.doi.org/10.1016/j.vaccine.2010.04.008
179. Esposito S, Tansey S, Thompson A., Razmpour A, Liang J, Jones T.R., Ferrera G., Maida A, Bona G, Sabatini C., et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol 2010; 17: 1017-26; PMID: 20427630; http://dx.doi.org/10.1128/CVI.00062-10
180. Yeh SH, Gurtman A, Hurley D.C., Block SL, Schwartz RH, Patterson S, Jansen K.U., Love J., Gruber WC, Emini EA, et al.; 004 Study Group. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics 2010; 126: e493-505; PMID: 20732948; http://dx.doi.org/10.1542/peds.2009-3027
181. Snape MD, Klinger CL, Daniels E.D., John TM, Layton H, Rollinson L, Pestridge S., Dymond S, Galiza E, Tansey S., et al. Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: A double-blind randomized active-controlled trial. Pediatr Infect Dis J 2010; 29: e80-90; PMID: 21155091; http://dx.doi.org/10. 1097/INF.0b013e3181faa6be
182. Vanderkooi O.G., Scheifele DW, Girgenti D, Halperin S.A., Patterson SD, Gruber WC, Emini EA, Scott D.A., Kellner JD; Canadian PCV13 Study Group. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada. Pediatr Infect Dis J 2012; 31: 72-7; PMID: 21960186; http://dx.doi.org/10.1097/ INF.0b013e318233049d
183. Huang LM, Lin TY, Juergens C. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccines in Taiwan. Vaccine 2012; 30: 2054-9; PMID: 22198517; http://dx.doi.org/10.1016/j.vaccine. 2011.12.054
184. Amdekar YK, Lalwani SK, Bavdekar A, Balasubramanian S., Chhatwal J, Bhat SR, Verghese V.P., Tansey SP, Gadgil D, Jiang Q, et al. Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers Given With Routine Vaccines in India. Pediatr Infect Dis J 2013; 32: 509-16; PMID: 23190777; http://dx.doi.org/10.1097/INF.0b013e31827b478d
185. Black SB, Shinefield HR, Hansen J, Elvin L., Laufer D, Malinoski F. Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2001; 20: 1105-7; PMID: 11740313; http://dx.doi.org/10.1097/00006454-200112000-00002 (Pubitemid 34016419)
186. Black SB, Shinefield HR, Ling S, Hansen J., Fireman B, Spring D, Noyes J., Lewis E, Ray P, Lee J., et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 2002; 21: 810-5; PMID: 12352800; http://dx.doi.org/10.1097/00006454-200209000-00005
187. Whitney CG, Farley MM, Hadler J, Harrison L.H., Bennett NM, Lynfield R, Reingold A, Cieslak P.R., Pilishvili T., Jackson D, et al.; Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348: 1737-46; PMID: 12724479; http://dx.doi.org/10.1056/NEJMoa022823 (Pubitemid 36514704)
188. Black S, Shinefield H, Baxter R., Austrian R, Bracken L, Hansen J., Lewis E, Fireman B. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J 2004; 23: 485-9; PMID: 15194827; http://dx.doi.org/10.1097/01.inf.0000129685.04847.94 (Pubitemid 38802290)
189. Whitney CG, Pilishvili T, Farley M.M., Schaffner W., Craig AS, Lynfield R, Nyquist AC, Gershman K.A., Vazquez M., Bennett NM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: A matched case-control study. Lancet 2006; 368: 1495-502; PMID: 17071283; http://dx.doi.org/10.1016/S0140-6736(06)69637-2 (Pubitemid 44634693)
190. Sharma D, Baughman W, Holst A., Thomas S, Jackson D, da Gloria Carvalho M, Beall B, Satola S., Jerris R, Jain S, et al. Pneumococcal carriage and invasive disease in children before introduction of the 13-valent conjugate vaccine: comparison with the era before 7-valent conjugate vaccine. Pediatr Infect Dis J 2013; 32: e45-53; PMID: 23080290; http://dx.doi.org/10.1097/INF. 0b013e3182788fdd
191. Snape MD, Perrett KP, Ford K.J., John TM, Pace D, Yu LM, Langley J.M., McNeil S., Dull PM, Ceddia F, et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: A randomized controlled trial. JAMA 2008; 299: 173-84; PMID: 18182599; http://dx.doi.org/10.1001/jama.2007.29-c
192. Jackson LA, Baxter R, Reisinger K., Karsten A, Shah J, Bedell L., Dull PM; V59P13 Study Group. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. Clin Infect Dis 2009; 49: e1-10; PMID: 19476428; http://dx.doi.org/10.1086/599117
193. Perrett KP, Snape MD, Ford K.J., John TM, Yu LM, Langley JM, McNeil S, Dull P.M., Ceddia F., Anemona A, et al. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants. Pediatr Infect Dis J 2009; 28: 186-93; PMID: 19209097; http://dx.doi.org/10. 1097/INF.0b013e31818e037d
194. Jackson LA, Jacobson RM, Reisinger K.S., Anemona A., Danzig LE, Dull PM. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. Pediatr Infect Dis J 2009; 28: 86-91; PMID: 19116603; http://dx.doi.org/10.1097/ INF.0b013e31818a0237
195. Halperin SA, Diaz-Mitoma F, Dull P., Anemona A, Ceddia F. Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers. Eur J Clin Microbiol Infect Dis 2010; 29: 259-67; PMID: 20033465; http://dx.doi.org/10. 1007/s10096-009-0848-8
196. Black S, Klein NP, Shah J, Bedell L., Karsten A, Dull PM. Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2-10 years of age. Vacci ne 2010; 28: 657-63; PMID: 19895922; http://dx.doi.org/10.1016/j.vaccine.2009.10.104
197. Arguedas A, Soley C, Loaiza C., Rincon G, Guevara S, Perez A., Porras W, Alvarado O, Aguilar L., Abdelnour A, et al. Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines. Vacci ne 2010; 28: 3171-9; PMID: 20189491; http://dx.doi.org/10.1016/j.vaccine.2010.02.045
198. Gasparini R, Conversano M, Bona G., Gabutti G, Anemona A, Dull P.M., Ceddia F. Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis vaccine in adolescents and young adults. Clin Vaccine Immunol 2010; 17: 537-44; PMID: 20164251; http://dx.doi.org/10.1128/CVI.00436-09
199. Klein NP, Reisinger KS, Johnston W, Odrljin T., Gill CJ, Bedell L, Dull P. Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants. Pediatr Infect Dis J 2012; 31: 64-71; PMID: 22094635; http://dx.doi.org/10.1097/INF. 0b013e31823dce5c
200. Rennels M, King J Jr., Ryall R, Papa T., Froeschle J. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr Infect Dis J 2004; 23: 429-35; PMID: 15131466; http://dx.doi.org/10.1097/01.inf. 0000126297.28952.f8 (Pubitemid 38621482)
201. Granoff DM, Morgan A, Welsch JA. Persistence of group C anticapsular antibodies two to three years after immunization with an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine. Pediatr Infect Dis J 2005; 24: 132-6; PMID: 15702041; http://dx.doi.org/10.1097/01.inf. 0000151035.64356.f8 (Pubitemid 40250771)
202. Pichichero M, Casey J, Blatter M., Rothstein E, Ryall R, Bybel M., Gilmet G, Papa T. Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children. Pediatr Infect Dis J 2005; 24: 57-62; PMID: 15665711; http://dx.doi.org/10.1097/ 01.inf.0000148928.10057.86 (Pubitemid 40353317)
203. Macneil JR, Cohn AC, Zell E.R., Schmink S., Miller E, Clark T, Messonnier NE; Active Bacterial Core surveillance (ABCs) Team and MeningNet Surveillance Partners. Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine. Pediatr Infect Dis J 2011; 30: 451-5; PMID: 21206392
204. Pina LM, Bassily E, Machmer A., Hou V, Reinhardt A. Safety and immunogenicity of a quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants and toddlers: three multicenter phase III studies. Pediatr Infect Dis J 2012; 31: 1173-83; PMID: 22814965; http://dx.doi.org/10. 1097/INF.0b013e318268dfe4
205. Campbell JD, Edelman R, King JC Jr., Papa T., Ryall R, Rennels MB. Safety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharide-diphtheria toxoid conjugate vaccine given to healthy adults. J Infect Dis 2002; 186: 1848-51; PMID: 12447774; http://dx.doi.org/10.1086/345763 (Pubitemid 35463520)
206. Knuf M, Kieninger-Baum D, Habermehl P., Muttonen P, Maurer H, Vink P., Poolman J, Boutriau D. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine 2010; 28: 744-53; PMID: 19887137; http://dx.doi.org/10.1016/j.vaccine.2009.10.064
207. Ostergaard L, Lebacq E, Poolman J., Maechler G, Boutriau D. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years. Vaccine 2009; 27: 161-8; PMID: 18834910; http://dx.doi.org/10.1016/j.vaccine.2008.08.075
208. Vesikari T, Forstén A, Boutriau D., Bianco V, Van der Wielen M, Miller JM. A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2-10 years. Hum Vaccin Immunother 2012; 8: 1882-91; PMID: 23032168; http://dx.doi.org/10.4161/hv.22165
209. Vesikari T, Karvonen A, Bianco V., Van der Wielen M, Miller J. Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella- varicella vaccine during the second year of life: An open, randomized controlled trial. Vac cine 2011; 29: 4274-84; PMID: 21443965; http://dx.doi.org/10.1016/j. vaccine.2011.03.043
210. Memish ZA, Dbaibo G, Montellano M., Verghese VP, Jain H, Dubey AP, Bianco V, Van der Wielen M, Gatchalian S, Miller JM. Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile. Pediatr Infect Dis J 2011; 30: e56-62; PMID: 21278617; http://dx.doi.org/10.1097/INF.0b013e31820e6e02
211. Baxter R, Baine Y, Ensor K., Bianco V, Friedland LR, Miller JM. Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age. Pediatr Infect Dis J 2011; 30: e41-8; PMID: 21200360; http://dx.doi.org/10.1097/INF.0b013e3182054ab9
212. Bermal N, Huang LM, Dubey A.P., Jain H., Bavdekar A, Lin TY, Bianco V, Baine Y., Miller JM. Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults. Hum Vaccin 2011; 7: 239-47; PMID: 21343698; http://dx.doi.org/10.4161/hv.7.2.14068
213. Dbaibo G, Macalalad N, Aplasca-De Los Reyes MR, Dimaano E, Bianco V., Baine Y, Miller J. The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine: A randomized, controlled non-inferiority study. Hum Vaccin Immunother 2012; 8: 873-80; PMID: 22485050; http://dx.doi.org/10.4161/hv.20211
214. Marshall GS, Marchant CD, Blatter M, Friedland L.R., Aris E., Miller JM. Co-administration of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine does not interfere with the immune response to antigens contained in infant vaccines routinely used in the United States. Hum Vaccin 2011; 7: 258-64; PMID: 21307655; http://dx.doi.org/10.4161/hv.7.2.14170
215. Nolan T, Richmond P, Marshall H., McVernon J, Alexander K, Mesaros N., Aris E, Miller J, Poolman J., Boutriau D. Immunogenicity and safety of an investigational combined haemophilus influenzae type B-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine. Pediatr Infect Dis J 2011; 30: 190-6; PMID: 20948453; http://dx.doi.org/10.1097/INF.0b013e3181fcb2bf
216. Eskola J, Kilpi T, Palmu A., Jokinen J, Haapakoski J, Herva E., Takala A, Käyhty H, Karma P., Kohberger R, et al.; Finnish Otitis Media Study Group. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001; 344: 403-9; PMID: 11172176; http://dx.doi.org/10.1056/ NEJM200102083440602 (Pubitemid 32128672)
217. O'Brien K.L., Moulton LH, Reid R, Weatherholtz R., Oski J, Brown L, Kumar G., Parkinson A, Hu D, Hackell J., et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet 2003; 362: 355-61; PMID: 12907008; http://dx.doi.org/10.1016/ S0140-6736(03)14022-6 (Pubitemid 36945058)
218. Kilpi T, Ahman H, Jokinen J., Lankinen KS, Palmu A, Savolainen H, Grönholm M, Leinonen M., Hovi T, Eskola J, et al.; Finnish Otitis Media Study Group. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clin Infect Dis 2003; 37: 1155-64; PMID: 14557958; http://dx.doi.org/10.1086/378744 (Pubitemid 37372502)
219. Prymula R, Peeters P, Chrobok V., Kriz P, Novakova E, Kaliskova E., Kohl I, Lommel P, Poolman J., Prieels JP, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: A randomised double-blind efficacy study. Lancet 2006; 367: 740-8; PMID: 16517274; http://dx.doi.org/10.1016/S0140-6736(06)68304-9 (Pubitemid 43326292)
220. Prymula R, Chlibek R, Splino M., Kaliskova E, Kohl I, Lommel P., Schuerman L. Safety of the 11-valent pneumococcal vaccine conjugated to non-typeable Haemophilus influenzae-derived protein D in the first 2 years of life and immunogenicity of the co-administered hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio virus, Haemophilus influenzae type b and control hepatitis a vaccines. Vacci ne 2008; 26: 4563-70; PMID: 18602724; http://dx.doi.org/10.1016/j.vaccine.2008.05.080
221. Knuf M, Szenborn L, Moro M., Petit C, Bermal N, Bernard L., Dieussaert I, Schuerman L. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Pediatr Infect Dis J 2009; 28(Suppl): S97-108; PMID: 19325452; http://dx.doi.org/10.1097/INF. 0b013e318199f61b
222. Palmu AA, Jokinen J, Borys D., Nieminen H, Ruokokoski E, Siira L., Puumalainen T, Lommel P, Hezareh M., Moreira M, et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: A cluster randomised trial. Lancet 2013; 381: 214-22; PMID: 23158882; http://dx.doi.org/10.1016/S0140- 6736(12)61854-6
223. Wuorimaa T, Dagan R, Eskola J., Janco J, Ahman H, Leroy O., Käyhty H. Tolerability and immunogenicity of an eleven-valent pneumococcal conjugate vaccine in healthy toddlers. Pediatr Infect Dis J 2001; 20: 272-7; PMID: 11303829; http://dx.doi.org/10.1097/00006454-200103000-00011 (Pubitemid 32240266)
224. Wuorimaa T, Dagan R, Väkeväinen M, Bailleux F, Haikala R., Yaich M, Eskola J, Käyhty H. Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant. J Infect Dis 2001; 184: 1211-5; PMID: 11598848; http://dx.doi.org/10.1086/323648 (Pubitemid 33010478)
225. Puumalainen T, Zeta-Capeding MR, Käyhty H, Lucero M.G., Auranen K., Leroy O, Nohynek H. Antibody response to an eleven valent diphtheria-and tetanus-conjugated pneumococcal conjugate vaccine in Filipino infants. Pediatr Infect Dis J 2002; 21: 309-14; PMID: 12075762; http://dx.doi.org/10.1097/ 00006454-200204000-00010 (Pubitemid 34326869)
226. Klugman KP, Madhi SA, Huebner R.E., Kohberger R., Mbelle N, Pierce N; Vaccine Trialists Group. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003; 349: 1341-8; PMID: 14523142; http://dx.doi.org/10.1056/NEJMoa035060 (Pubitemid 37186212)
227. Puumalainen T, Dagan R, Wuorimaa T., Zeta-Capeding R, Lucero M, Ollgren J., Käyhty H, Nohynek H. Greater antibody responses to an eleven valent mixed carrier diphtheria- or tetanus-conjugated pneumococcal vaccine in Filipino than in Finnish or Israeli infants. Pediatr Infect Dis J 2003; 22: 141-9; PMID: 12586978; http://dx.doi.org/10.1097/01.inf.0000050459.74134.d5 (Pubitemid 36228131)
228. Puumalainen T, Ekström N, Zeta-Capeding R, Ollgren J, Jousimies K., Lucero M, Nohynek H, Käyhty H. Functional antibodies elicited by an 11-valent diphtheria-tetanus toxoid-conjugated pneu mococcalvaccine. J Infect Dis 2003; 187: 1704-8; PMID: 12751027; http://dx.doi.org/10.1086/375242 (Pubitemid 36667880)
229. Dagan R, Goldblatt D, Maleckar J.R., Yaïch M, Eskola J. Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components. Infect Immun 2004; 72: 5383-91; PMID: 15322036; http://dx.doi.org/10.1128/IAI.72.9.5383-5391.2004 (Pubitemid 39223427)
230. Lucero MG, Puumalainen T, Ugpo J.M., Williams G., Käyhty H, Nohynek H. Similar antibody concentrations in Filipino infants at age 9 months, after 1 or 3 doses of an adjuvanted, 11-valent pneumococcal diphtheria/tetanus- conjugated vaccine: A randomized controlled trial. J Infect Dis 2004; 189: 2077-84; PMID: 15143476; http://dx.doi.org/10.1086/420849 (Pubitemid 38692289)
231. Dagan R, Kayhty H, Wuorimaa T., Yaich M, Bailleux F, Zamir O., Eskola J. Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants. Pediatr Infect Dis J 2004; 23: 91-8; PMID: 14872172; http://dx.doi.org/10.1097/01.inf.0000109221.50972.53 (Pubitemid 38222778)
232. Cutts FT, Zaman SM, Enwere G, Jaffar S., Levine OS, Okoko JB, Oluwalana C, Vaughan A., Obaro SK, Leach A, et al.; Gambian Pneumococcal Vaccine Trial Group. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005; 365: 1139-46; PMID: 15794968; http://dx.doi.org/10.1016/S0140-6736(05)71876-6 (Pubitemid 40417563)
233. Vesikari T, Wysocki J, Chevallier B., Karvonen A, Czajka H, Arsène JP, Lommel P., Dieussaert I, Schuerman L. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 2009; 28(Suppl): S66-76; PMID: 19325449; http://dx.doi.org/10.1097/INF. 0b013e318199f8ef
234. Chan CY, Molrine DC, George S, Tarbell N.J., Mauch P., Diller L, Shamberger RC, Phillips N.R., Goorin A., Ambrosino DM. Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease. J Infect Dis 1996; 173: 256-8; PMID: 8537671; http://dx.doi.org/10.1093/infdis/173.1.256 (Pubitemid 26009677)
235. Leach A, Ceesay SJ, Banya W.A., Greenwood BM. Pilot trial of a pentavalent pneumococcal polysaccharide/protein conjugate vaccine in Gambian infants. Pediatr Infect Dis J 1996; 15: 333-9; PMID: 8866803; http://dx.doi.org/10.1097/00006454-199604000-00010 (Pubitemid 26119274)
236. King JC Jr., Vink PE, Farley JJ, Smilie M, Parks M, Lichenstein R. Safety and immunogenicity of three doses of a five-valent pneumococcal conjugate vaccine in children younger than two years with and without human immunodeficiency virus infection. Pediatrics 1997; 99: 575-80; PMID: 9093301; http://dx.doi.org/10.1542/peds.99.4.575 (Pubitemid 27176438)
237. Sorensen RU, Leiva LE, Giangrosso P.A., Butler B., Javier FC 3rd, Sacerdote DM, Bradford N, Moore C. Response to a heptavalent conjugate Streptococcus pneumoniae vaccine in children with recurrent infections who are unresponsive to the polysaccharide vaccine. Pediatr Infect Dis J 1998; 17: 685-91; PMID: 9726341; http://dx.doi.org/10.1097/00006454-199808000-00005 (Pubitemid 28388156)
238. Miernyk KM, Parkinson AJ, Rudolph K.M., Petersen KM, Bulkow LR, Greenberg DP, Ward J.I., Brenneman G., Reid R, Santosham M. Immunogenicity of a heptavalent pneumococcal conjugate vaccine in Apache and Navajo Indian, Alaska native, and non-native American children aged <2 years. Clin Infect Dis 2000; 31: 34-41; PMID: 10913393; http://dx.doi.org/10.1086/313907 (Pubitemid 32268935)
239. Obaro SK, Adegbola RA, Chang I, Banya W.A., Jaffar S., Mcadam KW, Greenwood BM. Safety and immunogenicity of a nonavalent pneumococcal vaccine conjugated to CRM197 administered simultaneously but in a separate syringe with diphtheria, tetanus and pertussis vaccines in Gambian infants. Pediatr Infect Dis J 2000; 19: 463-9; PMID: 10819345; http://dx.doi.org/10.1097/00006454- 200005000-00014 (Pubitemid 30307999)
240. Obaro SK, Enwere GC, Deloria M, Jaffar S., Goldblatt D, Brainsby K, Hallander H., McInnes P, Greenwood BM, McAdam KP. Safety and immunogenicity of pneumococcal conjugate vaccine in combination with diphtheria, tetanus toxoid, pertussis and Haemophilus influenzae type b conjugate vaccine. Pediatr Infect Dis J 2002; 21: 940-7; PMID: 12394817; http://dx.doi.org/10.1097/00006454- 200210000-00011 (Pubitemid 35176155)
241. Huebner RE, Mbelle N, Forrest B., Madore DV, Klugman KP. Immunogenicity after one, two or three doses and impact on the antibody response to coadministered antigens of a nonavalent pneumococcal conjugate vaccine in infants of Soweto, South Africa. Pediatr Infect Dis J 2002; 21: 1004-7; PMID: 12442020; http://dx.doi.org/10.1097/00006454-200211000-00006 (Pubitemid 35334506)
242. Kumar D, Rotstein C, Miyata G., Arlen D, Humar A. Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients. J Infect Dis 2003; 187: 1639-45; PMID: 12721944; http://dx.doi.org/10.1086/374784 (Pubitemid 36578970)
243. Nachman S, Kim S, King J., Abrams EJ, Margolis D, Petru A, Shearer W., Smith E, Moye J, Blanchard S., et al.; Pediatric AIDS Clinical Trials Group Study 292 Team. Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection. Pediatrics 2003; 112: 66-73; PMID: 12837869; http://dx.doi.org/10.1542/peds. 112.1.66 (Pubitemid 36792931)
244. Madhi SA, Klugman KP, Kuwanda L, Cutland C., Käyhty H, Adrian P. Quantitative and qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIV-infected and HIV-uninfected children 5 years after vaccination. J Infect Dis 2009; 199: 1168-76; PMID: 19265481; http://dx.doi.org/10.1086/597388
245. Cordonnier C, Labopin M, Chesnel V., Ribaud P, De La Camara R, Martino R, Ullmann A.J., Parkkali T., Locasciulli A, Yakouben K, et al.; Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation. Clin Infect Dis 2009; 48: 1392-401; PMID: 19368505; http://dx.doi.org/10.1086/598324
246. Anderson EL, Bowers T, Mink C.M., Kennedy DJ, Belshe RB, Harakeh H, Pais L., Holder P, Carlone GM. Safety and immunogenicity of meningococcal a and C polysaccharide conjugate vaccine in adults. Infect Immun 1994; 62: 3391-5; PMID: 8039909 (Pubitemid 24232125)
247. Harris SL, Finn A, Granoff DM. Disparity in functional activity between serum anticapsular antibodies induced in adults by immunization with an investigational group a and C Neisseria meningitidis-diphtheria toxoid conjugate vaccine and by a polysaccharide vaccine. Infect Immun 2003; 71: 3402-8; PMID: 12761124; http://dx.doi.org/10.1128/IAI.71.6.3402-3408.2003 (Pubitemid 36637568)
248. Musher DM, Rueda AM, Nahm M.H., Graviss EA, Rodriguez-Barradas MC. Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia. J Infect Dis 2008; 198: 1019-27; PMID: 18710324; http://dx.doi.org/10.1086/591629
249. Reisinger KS, Baxter R, Block S.L., Shah J., Bedell L, Dull PM. Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra. Clin Vaccine Immunol 2009; 16: 1810-5; PMID: 19812260; http://dx.doi.org/10.1128/CVI.00207-09
250. Miernyk KM, Butler JC, Bulkow L.R., Singleton RJ, Hennessy TW, Dentinger CM, Peters H.V., Knutsen B., Hickel J, Parkinson AJ. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age. Clin Infect Dis 2009; 49: 241-8; PMID: 19522655; http://dx.doi.org/10.1086/599824
251. Stamboulian D, Lopardo G, Lopez P., Cortes-Barbosa C, Valencia A, Bedell L., Karsten A, Dull PM. Safety and immunogenicity of an investigational quadrivalent meningococcal CRM(197) conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America. Int J Infect Dis 2010; 14: e868-75; PMID: 20655261; http://dx.doi.org/10.1016/j.ijid.2010.03.017
252. Lazarus R, Clutterbuck E, Yu L.M., Bowman J., Bateman EA, Diggle L, Angus B, Peto T.E., Beverley PC, Mant D, et al. A randomized study comparing combined pneumococcal conjugate and polysaccharide vaccination schedules in adults. Clin Infect Dis 2011; 52: 736-42; PMID: 21367726; http://dx.doi.org/10.1093/cid/ cir003
253. Schutze MP, Leclerc C, Vogel F.R., Chedid L. Epitopic suppression in synthetic vaccine models: analysis of the effector mechanisms. Cell Immunol 1987; 104: 79-90; PMID: 2433056; http://dx.doi.org/10.1016/0008-8749(87)90008-6 (Pubitemid 17012147)
254. Herzenberg LA, Tokuhisa T, Herzenberg LA. Carrier-priming leads to hapten-specific suppression. Nature 1980; 285: 664-7; PMID: 6967189; http://dx.doi.org/10.1038/285664a0 (Pubitemid 10058188)
255. Schutze MP, Deriaud E, Przewlocki G., LeClerc C. Carrier-induced epitopic suppression is initiated through clonal dominance. J Immunol 1989; 142: 2635-40; PMID: 2467933 (Pubitemid 19114875)
256. Barington T, Kristensen K, Henrichsen J., Heilmann C. Influence of prevaccination immunity on the human B-lymphocyte response to a Haemophilus influenzae type b conjugate vaccine. Infect Immun 1991; 59: 1057-64; PMID: 1997409
257. Barington T, Skettrup M, Juul L., Heilmann C. Non-epitope-specific suppression of the antibody response to Haemophilus influenzae type b conjugate vaccines by preimmunization with vaccine components. Infect Immun 1993; 61: 432-8; PMID: 7678586 (Pubitemid 23030827)
258. Dagan R, Eskola J, Leclerc C., Leroy O. Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect Immun 1998; 66: 2093-8; PMID: 9573094 (Pubitemid 28194107)
259. Renjifo X, Wolf S, Pastoret P.P., Bazin H., Urbain J, Leo O, Moser M. Carrier-induced, hapten-specific suppression: A problem of antigen presentation? J Immunol 1998; 161: 702-6; PMID: 9670945 (Pubitemid 28323532)
260. Fattom A, Cho YH, Chu C, Fuller S., Fries L, Naso R. Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines. Vac cine 1999; 17: 126-33; PMID: 9987146; http://dx.doi.org/10.1016/S0264-410X(98)00162-5 (Pubitemid 28494111)
261. Rennels MB, Englund JA, Bernstein D.I., Losonsky GA, Anderson EL, Pichichero ME, Munoz F.M., Wolff MC. Diminution of the anti-polyribosylribitol phosphate response to a combined diphtheria-tetanus-acellular pertussis/Haemophilus influenzae type b vaccine by concurrent inactivated poliovirus vaccination. Pediatr Infect Dis J 2000; 19: 417-23; PMID: 10819337; http://dx.doi.org/10.1097/00006454-200005000-00006 (Pubitemid 30307991)
262. Lin TY, Wang YH, Chang L.Y., Chiu CH, Huang YC, Tang H, Bock HL. Safety and immunogenicity of a diphtheria, tetanus, and acellu lar pertussis- inactivated poliovirus vaccine/Haemophilus influenzae type B combination vaccine administered to Taiwanese infants at 2, 4, and 6 months of age. Chang Gung Med J 2003; 26: 315-22; PMID: 12934847 (Pubitemid 36988490)
263. Carlsson RM, Claesson BA, Selstam U, Fagerlund E., Granström M, Blondeau C., Hoffenbach A. Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age. Pediatr Infect Dis J 1998; 17: 1026-33; PMID: 9849987; http://dx.doi.org/10. 1097/00006454-199811000-00013 (Pubitemid 28549425)
264. Gold R, Scheifele D, Barreto L., Wiltsey S, Bjornson G, Meekison W., Guasparini R, Medd L. Safety and immunogenicity of Haemophilus influenzae vaccine (tetanus toxoid conjugate) administered concurrently or combined with diphtheria and tetanus toxoids, pertussis vaccine and inactivated poliomyelitis vaccine to healthy infants at two, four and six months of age. Pediatr Infect Dis J 1994; 13: 348-55; PMID: 8072815; http://dx.doi.org/10.1097/00006454- 199405000-00004 (Pubitemid 24145677)
265. Jones IG, Tyrrell H, Hill A., Horobin JM, Taylor B. Randomised controlled trial of combined diphtheria, tetanus, whole-cell pertussis vaccine administered in the same syringe and separately with Haemophilus influenzae type b vaccine at two, three and four months of age. Vaccine 1998; 16: 109-13; PMID: 9607017; http://dx.doi.org/10.1016/S0264-410X(97)00161-8 (Pubitemid 27504812)
266. Burrage M, Robinson A, Borrow R., Andrews N, Southern J, Findlow J., Martin S, Thornton C, Goldblatt D., Corbel M, et al. Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection. Infect Immun 2002; 70: 4946-54; PMID: 12183540; http://dx.doi.org/10.1128/IAI.70.9.4946-4954.2002
267. Trotter CL, Ramsay ME, Slack MP. Rising incidence of Haemophilus influenzae type b disease in England and Wales indicates a need for a second catch-up vaccination campaign. Commun Dis Public Health 2003; 6: 55-8; PMID: 12736974
268. Swartley JS, Marfin AA, Edupuganti S, Liu L.J., Cieslak P., Perkins B, Wenger JD, Stephens DS. Capsule switching of Neisseria meningitidis. Proc Natl Acad Sci USA 1997; 94: 271-6; PMID: 8990198; http://dx.doi.org/10.1073/pnas.94. 1.271 (Pubitemid 27027199)
269. Ko KS, Baek JY, Song JH. Capsular gene sequences and genotypes of 'serotype 6E' Streptococcus pneumoniae isolates. J Clin Microbiol 2013; PMID: 23824778; http://dx.doi.org/10.1128/JCM.01645-13
270. Richter SS, Heilmann KP, Dohrn C.L., Riahi F., Diekema DJ, Doern GV. Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999-2011(1.). Emerg Infect Dis 2013; 19: 1074-83; PMID: 23763847; http://dx.doi.org/10.3201/eid1907.121830
271. Moffitt K.L., Malley R. Next generation pneumococcal vaccines. Curr Opin Immunol 2011; 23: 407-13; PMID: 21514128; http://dx.doi.org/10.1016/j.coi.2011. 04.002
272. Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011; 378: 1962-73; PMID: 21492929; http://dx.doi.org/10.1016/S0140-6736(10)62225-8
273. Beall BW, Gertz RE, Hulkower R.L., Whitney CG, Moore MR, Brueggemann AB. Shifting genetic structure of invasive serotype 19A pneumococci in the United States. J Infect Dis 2011; 203: 1360-8; PMID: 21398395; http://dx.doi.org/10. 1093/infdis/jir052
274. Pichichero ME, Casey JR. Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA 2007; 298: 1772-8; PMID: 17940232; http://dx.doi.org/10.1001/jama.298.15.1772 (Pubitemid 47598445)
275. Blum MD, Dagan R, Mendelman P.M., Pinsk V., Giordani M, Li S, Bohidar N., McNeely TB. A comparison of multiple regimens of pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine and pneumococcal polysaccharide vaccine in toddlers. Vaccine 2000; 18: 2359-67; PMID: 10738092; http://dx.doi.org/10.1016/S0264-410X(00)00021-9 (Pubitemid 30156806)
276. Zangwill KM, Greenberg DP, Chiu C.Y., Mendelman P., Wong VK, Chang SJ, Partridge S, Ward JI. Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants. Vac cine 2003; 21: 1894-900; PMID: 12706674; http://dx.doi.org/10.1016/S0264-410X(03)00013-6 (Pubitemid 36428778)